ALNAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Allena Pharmaceuticals's gross profit for the three months ended in Jun. 2022 was $0.00 Mil. Allena Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Allena Pharmaceuticals's gross profit for the three months ended in Jun. 2022 was $0.00 Mil. Allena Pharmaceuticals's Revenue for the three months ended in Jun. 2022 was $0.00 Mil. Therefore, Allena Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2022 was N/A%.
Allena Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage
The historical data trend for Allena Pharmaceuticals's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Gross Profit | Get a 7-Day Free Trial | - | - | - | - | - |
Allena Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Gross Profit | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Allena Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Gross Profit distribution charts can be found below:
* The bar in red indicates where Allena Pharmaceuticals's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Allena Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as
Gross Profit (A: Dec. 2021 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Allena Pharmaceuticals's Gross Profit for the quarter that ended in Jun. 2022 is calculated as
Gross Profit (Q: Jun. 2022 ) | = | Revenue | - | Cost of Goods Sold |
= | 0 | - | 0 | |
= | 0.00 |
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Allena Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2022 is calculated as
Gross Margin % (Q: Jun. 2022 ) | = | Gross Profit (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.00 | / | 0 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Allena Pharmaceuticals (OTCPK:ALNAQ) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Allena Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Jun. 2022 => No sustainable competitive advantage
Thank you for viewing the detailed overview of Allena Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Louis Md Brenner | officer: See Remarks | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140 |
Mark J. Fitzpatrick | director | 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Richard D Katz | officer: Chief Financial Officer | 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703 |
Edward Wholihan | officer: Chief Financial Officer | C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Ann Calby Miller | director | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Allene M. Diaz | director | C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Hack Andrew A. F. | director | 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
Bessemer Venture Partners Vii L.p. | 10 percent owner | C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538 |
Hbm Biocapital Ii Lp | 10 percent owner | 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH |
James N Topper | director, 10 percent owner | 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301 |
Fhm Vi, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Robert I Tepper | director, 10 percent owner | 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215 |
Third Rock Ventures Ii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Robert Alexander | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Alexey L Margolin | director, officer: Chief Executive Officer | C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired Marketwired • 09-29-2021
By Marketwired Marketwired • 07-12-2021
By PRNewswire PRNewswire • 11-03-2021
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire PRNewswire • 06-01-2022
By Marketwired Marketwired • 08-03-2021
By GuruFocusNews GuruFocusNews • 05-04-2022
By PRNewswire PRNewswire • 07-01-2022
By GlobeNewswire GlobeNewswire • 07-14-2021
By Marketwired Marketwired • 07-08-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.